The EE is shown in Table IV and Fig. 2 a represented the graphical presentation of EE for all formulations. The results obtained for the drug EE ranged from 68 to 87%. The use of sonication for solubilisation of ACV in organic solvent allowed it to be correctly attached to lecithin and get encapsulated into nanoparticles formed.
Table 4 Observed and predicted value of encapsulation efficiency (Y1), particle size (Y2) and zeta potential (Y3) of formulations in the Box-Behnken design
Sample EE, % (Y1) Zeta potential, mV (Y2) Particle size, nm (Y3) PDI
Observed Predicted Observed Predicted Observed Predicted
PALN1 83.81 ± 1.93 84.84 37.70 ± 1.16 37.19 187.7 ± 3.75 186.09 0.238 ± 0.01
PALN2 82.15 ± 6.26 81.07 48.33 ± 1.93 50.39 264.8 ± 12.21 254.17 0.429 ± 0.12
PALN3 77.28 ± 0.58 78.00 43.73 ± 5.78 44.00 177.7 ± 5.23 180.51 0.216 ± 0.01
PALN4 83.44 ± 2.47 82.77 35.03 ± 1.76 33.20 231.7 ± 6.32 241.17 0.228 ± 0.02
PALN5 74.17 ± 6.10 72.42 31.37 ± 1.48 31.60 187.9 ± 9.56 186.76 0.243 ± 0.01
PALN6 68.45 ± 1.79 68.81 50.47 ± 1.65 48.13 186.8 ± 8.98 194.69 0.232 ± 0.02
PALN7 70.17 ± 9.14 71.92 42.07 ± 1.21 41.83 254.8 ± 15.45 256.00 0.237 ± 0.00
PALN8 84.72 ± 1.90 85.44 25.47 ± 1.33 28.09 156.4 ± 8.98 162.83 0.314 ± 0.01
PALN9 86.67 ± 3.27 85.44 31.17 ± 1.33 28.09 178.7 ± 10.54 162.87 0.179 ± 0.03
PALN10 84.67 ± 3.56 85.44 27.63 ± 2.94 28.09 166.1 ± 3.65 162.87 0.244 ± 0.01
PALN11 83.97 ± 1.52 83.61 21.30 ± 2.48 23.63 198.1 ± 4.78 190.29 0.167 ± 0.02
PALN12 83.57 ± 2.03 84.64 20.77 ± 5.59 18.70 240.2 ± 4.56 250.82 0.208 ± 0.03
PALN13 74.13 ± 4.69 73.10 39.73 ± 1.60 40.24 254.7 ± 16.87 256.30 0.347 ± 0.07
PALN14 70.86 ± 3.61 71.53 24.20 ± 1.56 26.02 251.5 ± 24.56 242.08 0.360 ± 0.07
PALN15 81.77 ± 6.41 81.06 22.83 ± 2.28 22.55 249.2 ± 16.87 246.42 0.344 ± 0.03
PALN16 86.09 ± 2.93 85.44 28.49 ± 1.76 28.10 157.5 ± 3.45 162.83 0.263 ± 0.01
PALN17 85.06 ± 2.88 85.44 27.69 ± 1.97 28.10 155.3 ± 7.65 162.82 0.228 ± 0.02